| Dr Thomas J Mathews, MD | |
|
2200 Forest Ridge Pkwy, Suite #240, New Castle, IN 47362-2943 | |
| (765) 521-7385 | |
| (765) 521-7394 |
| Full Name | Dr Thomas J Mathews |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 35 Years |
| Location | 2200 Forest Ridge Pkwy, New Castle, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689760753 | NPI | - | NPPES |
| 100379760 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 01042474 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Suburban Home Health Llc | Noblesville, IN | Home health agency |
| Omni Home Care | Richmond, IN | Home health agency |
| Hcmh Home Care | New castle, IN | Home health agency |
| Henry County Memorial Hospital | New castle, IN | Hospital |
| Reid Hospital & Health Care Services | Richmond, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cutting Edge Physical Therapy Limited Partnership | 6406869163 | 35 |
| New Castle Clinic Inc | 3274528757 | 37 |
News Archive
The National Institute of Mental Health estimates that in any given year, about 40 million adults (18 or older) will suffer from some form of anxiety disorder, including debilitating conditions such as phobias, panic disorders and post-traumatic stress disorder (PTSD). It is estimated that nearly 15 percent of U.S. soldiers returning from Iraq and Afghanistan develop PTSD, underscoring the urgency to develop better treatment strategies for anxiety disorders.
Scientists at Sanford Burnham Prebys Medical Discovery Institute, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore in Rome have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring (fibrosis).
Chronic obstructive pulmonary disease (COPD) is a progressive disorder that is often not diagnosed until a patient is over 60 years old and has substantial airflow obstruction. At this stage, it can be difficult to manage and treat the condition. To identify those at risk and intervene earlier, several studies have examined risk factors for COPD.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
› Verified 2 days ago
| Entity Name | Henry County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891570537 PECOS PAC ID: 6002724085 Enrollment ID: O20031121000221 |
News Archive
The National Institute of Mental Health estimates that in any given year, about 40 million adults (18 or older) will suffer from some form of anxiety disorder, including debilitating conditions such as phobias, panic disorders and post-traumatic stress disorder (PTSD). It is estimated that nearly 15 percent of U.S. soldiers returning from Iraq and Afghanistan develop PTSD, underscoring the urgency to develop better treatment strategies for anxiety disorders.
Scientists at Sanford Burnham Prebys Medical Discovery Institute, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore in Rome have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring (fibrosis).
Chronic obstructive pulmonary disease (COPD) is a progressive disorder that is often not diagnosed until a patient is over 60 years old and has substantial airflow obstruction. At this stage, it can be difficult to manage and treat the condition. To identify those at risk and intervene earlier, several studies have examined risk factors for COPD.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
› Verified 2 days ago
| Entity Name | New Castle Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801964960 PECOS PAC ID: 3274528757 Enrollment ID: O20041111000692 |
News Archive
The National Institute of Mental Health estimates that in any given year, about 40 million adults (18 or older) will suffer from some form of anxiety disorder, including debilitating conditions such as phobias, panic disorders and post-traumatic stress disorder (PTSD). It is estimated that nearly 15 percent of U.S. soldiers returning from Iraq and Afghanistan develop PTSD, underscoring the urgency to develop better treatment strategies for anxiety disorders.
Scientists at Sanford Burnham Prebys Medical Discovery Institute, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore in Rome have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring (fibrosis).
Chronic obstructive pulmonary disease (COPD) is a progressive disorder that is often not diagnosed until a patient is over 60 years old and has substantial airflow obstruction. At this stage, it can be difficult to manage and treat the condition. To identify those at risk and intervene earlier, several studies have examined risk factors for COPD.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas J Mathews, MD Po Box 530, Suite 240, New Castle, IN 47362-0530 Ph: (765) 521-7385 | Dr Thomas J Mathews, MD 2200 Forest Ridge Pkwy, Suite #240, New Castle, IN 47362-2943 Ph: (765) 521-7385 |
News Archive
The National Institute of Mental Health estimates that in any given year, about 40 million adults (18 or older) will suffer from some form of anxiety disorder, including debilitating conditions such as phobias, panic disorders and post-traumatic stress disorder (PTSD). It is estimated that nearly 15 percent of U.S. soldiers returning from Iraq and Afghanistan develop PTSD, underscoring the urgency to develop better treatment strategies for anxiety disorders.
Scientists at Sanford Burnham Prebys Medical Discovery Institute, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore in Rome have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring (fibrosis).
Chronic obstructive pulmonary disease (COPD) is a progressive disorder that is often not diagnosed until a patient is over 60 years old and has substantial airflow obstruction. At this stage, it can be difficult to manage and treat the condition. To identify those at risk and intervene earlier, several studies have examined risk factors for COPD.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
› Verified 2 days ago
Clayton Edward Strong, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite 240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 | |
Anjan P Kaushik, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, New Castle, IN 47362 Phone: 765-521-7385 | |
Dr. Kyle William Siewert, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite 240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 | |
Dr. Lindsey R Rolston, M.D Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite #240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 | |
Dr. Damion M. Harris, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Forest Ridge Pkwy, Suite #240, New Castle, IN 47362 Phone: 765-521-7385 Fax: 765-521-7394 |